1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €3.01 (+56.77%). The median is €3.01 (+56.77%).
| Buy |
1 |
| Hold |
2 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | |
|---|---|---|
| Revenue | 23.62K | 97.76% |
| Gross profit | 10.21K | 97.99% |
| Net profit | -600.69K | 73.08% |
| EBITDA | -625.39K | 71.84% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €13.48M |
Number of shares | 7.02M |
52-week high/low | €8.23 - €1.51 |
| Dividends | No |
Beta | 1.51 |
P/E ratio | -0.07 |
PEG ratio | 0.00 |
P/B ratio | 2.59 |
P/S ratio | 120.65 |
Company profile
| Name | ReShape Lifesciences |
| CEO | Venkateswarlu Nelabhotla |
| Employees | 18 |
Discover assets
Shareholders of ReShape Lifesciences also invest in the following assets
